No abstract

90 Background: RWED denotes data accumulated via EHR as well as cutting edge technology paired with consumer mobile devices. We are reporting data on 105 pts, users of Belong.life, a worldwide mobile application, who received immunotherapy for their various cancers and were asked to reply to a short, targeted survey on their FT while on treatment. Methods: 105 pts anonymously and voluntarily replied to a survey which included 14 general information questions and those describing FT, its most common encountered causes and their personal financial coping strategies. Results: 79% of the pts were USA based. 21% of the pts were < 50 years of age (yoa), 32% were 51-60 yoa and 47% were > 61 yoa. Pts’s stages were Stage 3 in 23% and 4 in 62% with unknown in 15%. There were 36% males and 64% females. The most common cancer diagnosis was lung in 46% followed by kidney in 17%, malignant melanoma in 14% and colorectal in 10%. The prevalent immunotherapy drugs were nivolumab and pembrolizumab in 36% respectively, and ipilimumab in 14% and durvalumab in 10%. Frequently reported FTs were high medical copayments in 35% of the pts, loss of income in 33% and high drugs and treatments copayments in 21%. 41% of the pts were insured by Medicare and 25% by Medicaid and other HMOs. Only 48% of the pts were aware of possible financial difficulties as a result of their diagnosis and treatment, and 34% received pre-treatment financial advice from their doctors which reduced the reported FT from 48% to 30%. When asked about coping strategies, 39% used personal savings, 28% trimmed their private expenses, and 24% received financial support from their families and friends. Conclusions: 105 users of the Belong.life application reported on their FTs experienced while receiving cancer immunotherapy. FT was most prevalent in the older group ( > 61 yoa) due to high medical and treatment copayments. Nearly half of the pts was not aware of the possible FT and only 38% received advisory information from their doctors. Reduced FT prevalence (from 48% to 30%) was reported by those informed pts. Physicians should become aware of their pts’s possible risks for FTs, therefore appropriate advice should be given prior to immunotherapy initiation.

the vaccination. Here, we evaluated attitude towards and effects of COVID-19 vaccination in patients with breast or gynecological cancer. The aim was to improve counseling of our patients in clinical routine.Methods: Since March 15 th 2021, patients who received one of the approved COVID-19 vaccines were routinely interviewed about immediate (0-2 days) and late side effects (within two weeks after vaccination). Clinical parameters such as current therapy, time interval between therapy administration and vaccination, and changes in the therapy schedule due to the vaccination were documented. Furthermore, the willingness of non-vaccinated patients to be vaccinated was assessed. The collected data were anonymously analyzed as a part of routine quality assurance.Results: By May 10 th 2021, 111 out of 217 (51.1%) interviewed patients had received at least one shot of COVID-19 vaccine and 21 patients both shots. More than half of the vaccinated patients were >55y (60.2%; mean: 60.7y, range 30-92y); 69% with UICC/ FIGO stage III/IV cancer. 74.6% received Conmirnaty (BioNTech/ Pfizer), 18.9% Vaxzevria (AstraZeneca) and 6.5% Covid-19 Vaccine Moderna. After the first shot, 33.3% of the patients described no side effects, 49.1% reported a local reaction (swelling or pain), 23.4% flu-like symptoms, 10.8% headache and 3.6% nausea. 11 patients had symptoms that lasted longer than two days. In 11 cases, COVID-19 vaccination had an impact on delivery of the systemic therapy (n¼10 postponements of therapy and n¼1 dose reduction). 61.3% of the non-vaccinated patients (in total n¼118) were already registered to get vaccinated; 32.8% chose to postpone vaccination for personal reasons; 5% refused vaccination.Conclusions: Breast and gynecological cancer patients appear to tolerate COVID-19 vaccination well under systemic therapy and only in few cases the vaccination interfered with the treatment schedule. Updated results will be presented at the ESMO Congress.

was present in field 1 or 2 on the claim. Descriptive analyses used per-patient-permonth (PPPM) measures and the Kaplan-Meier method.Results: Among pts treated with ICI monotherapy with irAEs (N¼955; 71 y, 54% male, 69% with treatment before ICI), the top HCRU for irAEs was ambulatory visits (0.23 PPPM), followed by inpatient stays (0.09 PPPM; Table ). Mean irAE-related medical costs were $2,359 PPPM, driven by the cost of inpatient stays. 34% of all pts who experienced an irAE had an irAE-related inpatient stay within 12 mo after ICI initiation.Conclusions: Inpatient stays were the driver for irAE-related costs; approximately onethird of pts with an irAE ultimately required an inpatient stay within a year of initiating ICIs. These study findings help elucidate the economic burden associated with the management of ICI irAEs.

e18060 Background: RWD denotes data accumulated via electronic health records as well as cutting edge technology paired with consumer mobile devices. Artificial intelligence (AI) incorporates the use of algorithms and machine learning (ML) software to analyze complex medical data, improving the knowledge of cancer journeys. PRO on 256 BC patients (pts) survey repliers, users of Belong.life, a worldwide social media application for cancer pts, are presented. Methods: From 11/2018 to 01/2019, 256 pts replied to a 37 questions’ survey which included information regarding clinical and emotional S/E, FT and CM use. Results: 98 pts (38%) were < 50 years of age, 158 (62%) > 50 years. Most of the pts (163, 64%) were diagnosed within 2017-8. Most pts had Stage 1 (83 pts,32%) and 2 (94 pts,37%) and 71 pts (28%) had Stage 3-4. 154 (61%) had neo-adjuvant anthracyclines-based treatments, followed by a taxane (docetaxel/paclitaxel). 149 of 256 pts (58%) reported clinical S/E: nausea and vomiting in 77 pts (52%), fatigue in 63 pts (42%), hair loss in 42 pts (28%) and body pain and neuropathy in 13 pts each (8.8%). 90 pts (35%) described various emotional symptoms: depression in 32 pts (35.6%), anxiety 13 (14.4%), ‘up and down’ feelings in 20 pts (22 %). FT was experienced by 100/208 pts (48%). FT was most prevalent in ages 35-50 (51/85pts, 60%) than in 51-65 (41/100pts, 41%). Main reported causes in both groups were loss or absence from work (33% and 51%) and treatment copayments (40% and 21%). CM use was reported by 42/256 pts (16.4%). Most common CM were nutritional, multivitamins, supplements and CBD oil use. ML documented a strong relationship between BC recurrence in 55/256 pts (21.5%), FT in 25/55 pts (45.5%) and CM use in 9/25 pts (36%) vs no FT in 3/30 pts (10%). Conclusions: 256 BC users of the Belong application reported on clinical and emotional S/E, FT and CM use. The high incidence of emotional S/E stresses the need for individualized attention. FT was most prevalent in the younger age group (35-50yrs) due to work loss and treatment copayments. A significant relationship was determined by ML techniques on those patients experiencing BC recurrence, FT and CM use.